Redeye retains its positive view on Transtema following the Q4 report despite a somewhat softer adju...
The Q4 report was slightly above our expectations when adjusting for earn-outs & divestments.
We expect a solid Q4 report for Ferronordic on 18 February, with sales up 37% y/y and adjusted EBIT ...
Serneke ended 2021 on a high note, reporting sales growth of 27% y/y.
Redeye takes a more positive stance towards Proact following the Q4 report, despite showing declinin...
Svedbergs avslutade 2021 med 16 procents organisk tillväxt och ett förvärv som fördubblar koncernens...
Redeye believes Sdiptech’s Q4 report and guidance will relieve the soft share price performance seen...
In Q4, we expect a solid report from MGI. The games segment has benefitted from a seasonally strong ...
Redeye leaves a comment on Respiratorious following the announcement of a SEK 45m fully guaranteed r...
Redeye comments on Cereno’s Q4 2021 report, concluding a year in which the company has made several ...
Redeye gives a short comment on the announced rights issue and pauses its coverage.
Nelly reported Q4 sales 1% above our forecast but EBIT SEK2m below.
Following Monday's announcement of the Xcimzane licensing deal with Biogen, Redeye is convinced that...
Försäljningstillväxt 47% y/y Försäljningen för 2021 uppgick till 185 mkr vs våra estimat om 173 mkr.
Stark omsättningstillväxt men lägre marginal Justerad nettoomsättning i Q4'21 uppgick till 186 mkr (...
Redeye endorses CLS entering into a clinical trial agreement with Skåne University Hospital to evalu...
Redeye provides a preview of its Q4'21 estimates for BONESUPPORT ahead of its report next week.
Finnair reports Q4 results Thu, Feb 17. In our view the latest pandemic twists do not stage any sign...
Earlier today, Alzecure reported that the company had received a supportive response from the FDA re...
Redeye comments on the SEK 2m order from a leading US oil company for Enviro’s pyrolysis oil.
